All In Biotech

BLA 022523 · Vivus INC

Pancreaze

Pancrelipase (Amylase, Lipase, Protease) · Oral

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Apr 12, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

n/a

n/a Phase 3, n/a recruiting

FAERS reports

678

365 serious, 49 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 6, 2025.

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )

Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • PANCREAZE · PANCRELIPASE (AMYLASE 149,900USP UNITS; LIPASE 37,000USP UNITS; PROTEASE) 97,300USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PANCREAZE · PANCRELIPASE (AMYLASE 98,400USP UNITS; LIPASE 16,800USP UNITS; PROTEASE) 56,800USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PANCREAZE · PANCRELIPASE (AMYLASE 24,600USP UNITS; LIPASE 4,200USP UNITS; PROTEASE) 14,200USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PANCREAZE · PANCRELIPASE (AMYLASE 15,200USP UNITS; LIPASE 2,600USP UNITS; PROTEASE) 8,800USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PANCREAZE · PANCRELIPASE (AMYLASE 83,900USP UNITS; LIPASE 21,000USP UNITS; PROTEASE) 54,700USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PANCREAZE · PANCRELIPASE (AMYLASE 61,500USP UNITS; LIPASE 10,500USP UNITS; PROTEASE) 35,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.

All n/a trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea63
  • drug dose omission36
  • death29
  • abdominal pain upper28
  • infective pulmonary exacerbation of cystic fibrosis27
  • nausea27
  • pneumonia27
  • pain25
  • cystic fibrosis23
  • drug ineffective23
  • vomiting22
  • abdominal pain20

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201016
201145
201233
201312
201410
201583
201657
201753
201845
201938
202069
202145
202233
202340
202444
202529
202626

Recalls

1 FDA enforcement reports for this application.

  • Jun 23, 2023 · Class III · Ongoing

    Failed Stability Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pancreaze (Lipase/Protease/Amylase)

2024 spending

$12.4M

Beneficiaries

2,375

7,942 claims

Per beneficiary

$5,235

$6.17 per unit

View as table
YearSpending
2020$7,241,895
2021$6,839,270
2022$8,180,968
2023$10,310,701
2024$12,433,009

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Vivus INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.